Skip to main content
OpenTrials
Completed

NCT Number: NCT01839968

Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acquired Platelet Disorder

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital of Geneva

Geneva, Canton of Geneva, 1205, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Acute coronary syndrome
  • Prasugrel loading dose 6-24h before inclusion

Exclusion criteria

  • Clopidogrel loading dose
  • GPIIbIIIa use within 10 days before inclusion
  • Known congenital thrombopathy and/or congenital coagulation defect

Treatment and study plan

Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma

Other

Primary outcomes

  1. Platelet reactivity assessed by light transmittance aggregometry (LTA) after ex-vivo normal platelet addition

    Time frame: within the first 6-24 hours after antiplatelet drug loading dose

Sponsors and collaborators

Lead sponsor

University Hospital, Geneva

Other

Registry information

Important dates

Study start
2011
Primary completion
2013
Study completion
2014
First posted
Apr 25, 2013
Registry last updated
Aug 19, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.